HCW Biologics Q4 revenue drops sharply on license suspension

Reuters04-01
<a href="https://laohu8.com/S/HCWB">HCW Biologics</a> Q4 revenue drops sharply on license suspension

Overview

  • U.S. biopharmaceutical firm's Q4 2025 revenue declined sharply yr/yr amid license suspension

  • Basic EPS for Q4 was -1.02, reflecting continued net losses

  • Company received $3.5 mln upfront license fee for HCW11-006 and launched two commercial-ready reagents

Outlook

  • Company says substantial doubt exists about ability to continue as going concern without additional funding

  • Company expects preliminary human data from HCW9302 Phase 1 trial in first half of 2026

  • Company plans to appeal Nasdaq notice on minimum bid price non-compliance

Result Drivers

  • LICENSE SUSPENSION - Revenue decline attributed to one-year suspension of Wugen license agreement, allowing co to market HCW9206 and HCW9201 as reagents

  • R&D SPENDING - Q4 R&D expenses increased 27% yr/yr, driven by ongoing clinical development activities

  • REAGENT LAUNCH - Co launched two proprietary fusion protein molecules as commercial-ready reagents to support cell-based immunotherapeutics production

Company press release: ID:nGNX1bkw6c

Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q4 Basic EPS

-$1.02

Analyst Coverage

  • The one available analyst rating on the shares is "buy"

  • The average consensus recommendation for the biotechnology & medical research peer group is "buy"

  • Wall Street's median 12-month price target for HCW Biologics Inc is $2.00, about 454.2% above its March 30 closing price of $0.36

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment